Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...
Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26
While the China-targeting Biosecure Act failed to pass muster in a key defense spending bill last year, a retooled version of ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
Gamida Cell has scored an expansion for Omisirge, with the FDA endorsing the stem cell-based therapy to treat severe aplastic ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback